Skip to main content

Table 1 Demographic and clinical characteristics of study subjects

From: Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus

 

SLE (n = 53)

RA (n = 52)

HD (n = 23)

Age (years)

40.9 ± 17.8

64.3 ± 15.7

38.1 ± 8.0

Females, n (%)

49 (92.5)

35 (67.3)

20 (87.0)

Disease duration (months)

140.4 ± 159.9

83.6 ± 127.1

 

SLEDAI score

4.9 ± 5.4

  

BILAG score

4.8 ± 6.6

  

Anti-dsDNA (U/ml)

34.4 ± 82.9

  

IgG (mg/dl)

1657 ± 710.8

1374 ± 396.3

 

CH50 (U/ml)

42.7 ± 14.1

  

C3 (mg/dl)

84.7 ± 29.2

  

C4 (mg/dl)

16.7 ± 9.1

  

CRP (mg/dl)

0.2 ± 0.4

1.5 ± 2.0

 

ESR (mm/h)

36.0 ± 31.3

42.0 ± 28.1

 

Prednisolone use at baseline, n (%)

36 (67.9)

18 (34.6)

 

Dose of prednisolone (mg/day)

3.1 ± 3.3

3.8 ± 9.6

 

Hydroxychloroquine use at baseline, n (%)

30 (56.6)

  

Immunosuppressant use at baseline

 Mycophenolate mofetil, n (%)

10 (18.9)

  

 Calcineurin inhibitors, n (%)

9 (17.0)

  

 Azathioprine, n (%)

4 (7.5)

  

 Methotrexate, n (%)

2 (3.8)

36 (69.2)

 

 Mizoribine, n (%)

2 (3.8)

  

 Leflunomide, n (%)

1 (1.9)

  
  1. Data are mean ± SD or percentage of patients
  2. SLEDAI Systemic Lupus Erythematosus Disease Activity Index, BILAG British Isle Lupus Assessment Group, Anti-dsDNA Anti-double-stranded DNA antibody, CRP C-reactive protein, ESR Erythrocyte sedimentation rate